MERS-CoV Spike protein S1 (aa 1-725) [His]

Name: MERS-CoV Spike protein S1 (aa 1-725) [His]
SKU: DAG-H10301
Rating: 5 (1 reviews)

MERS-CoV Spike protein S1 (aa 1-725) [His], recombinant protein from Baculovirus

COA

SDS

Datasheet

Summary

Nature

Recombinant

Predicted N terminal

Tyr 18

Tag/Conjugate

His

Endotoxin

< 1.0 EU per μg of the protein as determined by the LAL method

Application Notes

ELISA: 10 μg/mL

Purity

> 95 % as determined by SDS-PAGE

Format

Lyophilized from sterile 20mM Tris, 500mM NaCl, 10% glycerol, pH 7.4.

Preservative

None

Storage

Store it under sterile conditions at -70 °C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Stability

Samples are stable for up to twelve months from date of receipt at -70°C

Introduction

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell: they are essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV.

Keywords

Coronavirus; Corona; Coronaviridae; Coronavirinae

Citations

Have you cited DAG-H10301 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

MERS-CoV spike protein: a key target for antivirals

EXPERT OPINION ON THERAPEUTIC TARGETS

Authors: Du, Lanying; Yang, Yang; Zhou, Yusen; Lu, Lu; Li, Fang; Jiang, Shibo

Abstract

Introduction: The continual Middle East respiratory syndrome (MERS) threat highlights the importance of developing effective antiviral therapeutics to prevent and treat MERS coronavirus (MERS-CoV) infection. A surface spike (S) protein guides MERS-CoV entry into host cells by binding to cellular receptor dipeptidyl peptidase-4 (DPP4), followed by fusion between virus and host cell membranes. MERS-CoV S protein represents a key target for developing therapeutics to block viral entry and inhibit membrane fusion.Areas covered: This review illustrates MERS-CoV S protein's structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS-CoV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides.Expert opinion: No anti-MERS-CoV therapeutic is approved for human use. Several S-targeting neutralizing mAbs and peptides have demonstrated efficacy against MERS-CoV infection, providing feasibility for development. Generally, human neutralizing mAbs targeting RBD are more potent than those targeting other regions of S protein. However, emergence of escape mutant viruses and mAb's limitations make it necessary for combining neutralizing mAbs recognizing different neutralizing epitopes and engineering them with improved efficacy and reduced cost. Optimization of the peptide sequences is expected to produce next-generation anti-MERS-CoV peptides with improved potency.

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

EMERGING INFECTIOUS DISEASES

Authors: Okba, Nisreen M. A.; Mueller, Marcel A.; Li, Wentao; Wang, Chunyan; GeurtsvanKessel, Corine H.; Corman, Victor M.; Lamers, Mart M.; Sikkema, Reina S.; de Bruin, Erwin; Chandler, Felicity D.; Yazdanpanah, Yazdan; Le Hingrat, Quentin; Descamps, Diane; Houhou-Fidouh, Nadhira; Reusken, Chantal B. E. M.; Bosch, Berend-Jan; Drosten, Christian; Koopmans, Marion P. G.; Haagmans, Bart L.

Abstract

A new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged to cause a human pandemic. Although molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are needed for contact tracing, identifying the viral reservoir, and epidemiologic studies. We developed serologic assays for detection of SARS-CoV-2 neutralizing, spike protein-specific, and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed SARS-CoV-2 infections, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs. We demonstrated that most PCR-confirmed SARS-CoV-2-infected persons seroconverted by 2 weeks after disease onset. We found that commercial S1 IgG or IgA ELISAs were of lower specificity, and sensitivity varied between the 2 assays; the IgA ELISA showed higher sensitivity. Overall, the validated assays described can be instrumental for detection of SARS-CoV-2-specific antibodies for diagnostic, seroepidemiologic, and vaccine evaluation studies.